Chardan Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA - Free Report) in a research report report published on Thursday morning,Benzinga reports. Chardan Capital currently has a $14.00 price objective on the stock.
A number of other equities analysts have also commented on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research report on Thursday. HC Wainwright restated a "buy" rating and set a $18.00 price objective on shares of Coya Therapeutics in a report on Monday, November 11th.
View Our Latest Stock Analysis on COYA
Coya Therapeutics Trading Up 0.7 %
Shares of NASDAQ COYA traded up $0.05 during mid-day trading on Thursday, reaching $6.88. The company had a trading volume of 51,906 shares, compared to its average volume of 66,727. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.69. The business's 50-day moving average is $5.88 and its 200-day moving average is $6.38. The stock has a market cap of $114.96 million, a price-to-earnings ratio of -10.58 and a beta of 0.47.
Institutional Investors Weigh In On Coya Therapeutics
A number of institutional investors have recently added to or reduced their stakes in COYA. Geode Capital Management LLC boosted its holdings in shares of Coya Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company's stock valued at $918,000 after buying an additional 4,485 shares in the last quarter. CM Management LLC boosted its stake in Coya Therapeutics by 11.1% in the fourth quarter. CM Management LLC now owns 160,000 shares of the company's stock valued at $917,000 after acquiring an additional 15,941 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Coya Therapeutics in the second quarter worth $101,000. GHP Investment Advisors Inc. purchased a new position in Coya Therapeutics in the third quarter worth $169,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Coya Therapeutics during the fourth quarter worth $401,000. Institutional investors own 39.75% of the company's stock.
About Coya Therapeutics
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Recommended Stories
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
